Xilio Therapeutics, Inc.

In addition to our new collaboration with AbbVie announced earlier today, we are excited to unveil three wholly-owned preclinical programs for masked T cell engagers targeting PSMA, CLDN18.2 and STEAP1. To date, T cell engagers have demonstrated significant promise as cancer immunotherapies, but their potential has been limited by toxicity. Leveraging our clinically-validated tumor-activation platform, our masked T cell engagers are designed to enable potent, localized T cell activation and tumor cell destruction together with an improved therapeutic index. Learn more from the release: https://lnkd.in/e9vAa76G Join our conference call and webcast: https://lnkd.in/e53xmZyw

Today, we announced an exciting collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers. “This collaboration with AbbVie, a global leader in developing and commercializing oncology therapies, allows us to accelerate the expansion of our technology to next-generation immunotherapies, including T cell engagers,” said Carl Uli Bialucha, Ph.D., chief scientific officer of Xilio. “We look forward to working with the AbbVie team to apply our deep protein engineering expertise coupled with tumor-selective activation through our novel formats for masked T cell engagers.” Join us for an investor conference call and webcast today at 8:30 am EST. Learn more below and at https://lnkd.in/ezEEeQCd.

Today we shared initial Phase 2 data for vilastobart (XTX101), our tumor-activated anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable #ColorectalCancer (MSS CRC). These data are being presented at ASCO #GI25 and include a 27% preliminary objective response rate in heavily pre-treated MSS CRC patients without liver metastases and a differentiated safety and tolerability profile for the combination with minimal immune-related adverse events observed. We will host an investor conference call and webcast tomorrow, Wednesday, January 22, 2025, at 8:30 am ET, available at https://lnkd.in/e53xmZyw.

We are pleased to announce that we will be presenting initial Phase 2 data for vilastobart (XTX101), our tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with advanced MSS CRC at ASCO GI in January. In addition, today we announced preliminary data from our ongoing Phase 1 trial for XTX301, our tumor-activated IL-12. To learn more about the progress across our clinical-stage pipeline, read our press release: https://lnkd.in/guHGyQTb

We're very pleased to announce the appointment of Caroline Hensley as Xilio's chief legal officer. Caroline is an accomplished lawyer and biotech executive who brings extensive experience across both private and public biotech companies, most recently serving as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc. We’re thrilled to have Caroline on the team as we gear up for what promises to be an exciting new year for Xilio. Read more about her appointment here: https://lnkd.in/ePJubuB7

We're thrilled to announce that Xilio Therapeutics has been recognized as one of The Boston Globe Media's Top Places to Work in Massachusetts! Our employees are making vital contributions to our mission of developing innovative, tumor-activated immunotherapy treatments for people with cancer, and this award reflects the amazing and passionate people who make Xilio such a special place to work. #TopPlacesToWork #BiotechCareers #LifeSciences #WorkBoston

We’re excited to share initial Phase 1 data for vilastobart (XTX101), a tumor-activated, Fc-enhanced, anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors.   We’re hosting an investor conference call and webcast later today, Thursday, November 7, at 4:30 p.m. ET to discuss the data, which will be presented tomorrow in a late-breaker poster presentation at the Society for Immunotherapy of Cancer’s annual meeting, #SITC24 this weekend. Read more: https://lnkd.in/eDtYr6gV

We’re pleased to announce that we will be presenting at #SITC24. We look forward to sharing preclinical data from our SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format, during the poster sessions on Saturday, November 9th. Read more at https://lnkd.in/eppFnHGz We hope to see you at SITC: https://lnkd.in/ggphnMEm

It was a pleasure to welcome Parexel’s Chief Patient Officer, Stacy Hurt 🌻 as well as Luke Rosen, founder of Rescue 7 Firefighters for Patients and KIF1A.ORG, as speakers at our recent all-company meeting. Both Stacy and Luke, #ColorectalCancer advocates and survivors, shared their perspectives on patient-first clinical research and driving therapeutic solutions that make an impact. We had the honor to hear each of their stories from diagnosis to treatment, advocacy and parenting children with rare disorders. Their perspectives left a deep impression on the entire Xilio team, underscoring the critical need for new treatment options and how vitally important our work is. Testimonials like theirs spur our team to work even harder as we advance our pipeline of novel, tumor-activated I-O therapies. Thank you, Stacy and Luke, for joining us and for your courage and passion, and special thanks to our moderator, Tiffany Patrick, MPH, MBA, life science leader and global health advocate, for helping to facilitate this impactful conversation.

Alongside news of our Q2 2024 earnings and pipeline progress yesterday, we announced the promotion of Christopher Frankenfield to chief financial officer while continuing to serve in his role as chief operating officer. Chris has been integral to guiding Xilio's strategic growth since he joined us in 2021, and we are confident in his continued leadership as we advance our robust pipeline of tumor-activated immunotherapies to treat cancer. https://lnkd.in/eDzrgytg